Patients. Five hundred thirty-four adult military health care beneficiaries who received quetiapine at a total daily dose of 100 mg or less for a minimum of 1 month between January 1, 2005, and June 30, 2008.

Measurements and Main Results. The mean weight at baseline was 175.68 lbs. The mean ± standard error weight gain compared with baseline was 0.49 ± 0.51 lbs (p=0.335) at 1 month, increasing in a generally linear fashion to 5.56 ± 1.25 lbs (p<0.001) at 6 months, and 10.58 ± 2.20 lbs (p<0.001) at 12 months.

Conclusion. Low-dose quetiapine caused a statistically significant weight gain in our study population. This finding highlights the need for greater recognition of the potential for quetiapine to cause undesirable effects, and demonstrates the importance of close monitoring of physiologic parameters during treatment.

References

1 Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789–96.
10.1001/archpsyc.1988.01800330013001
CASPubMedWeb of Science®Google Scholar
2 Kelleher J., Centorrino F., Albert M., Baldessarini R. Advances in atypical antipsychotics for the treatment of schizophrenia. CNS Drugs 2002; 16: 249–61.
10.2165/00023210-200216040-00004
CASPubMedWeb of Science®Google Scholar
3 Meltzer H., McGurk S. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophren Bull 1999; 25: 233–55.
10.1093/oxfordjournals.schbul.a033376
CASPubMedWeb of Science®Google Scholar
4 Bergman R., Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66: 504–14.
10.4088/JCP.v66n0414
CASPubMedWeb of Science®Google Scholar
5 Allison D., Mentore J., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96.
10.1176/ajp.156.11.1686
CASPubMedWeb of Science®Google Scholar
6 Vestri H., Maianu L., Moellering D., Garvey W. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis and antilipolysis. Neuropsychopharmacology 2007; 32: 765–72.
10.1038/sj.npp.1301142
CASPubMedWeb of Science®Google Scholar
7 Kroeze W., Hufeisen S., Popadek B., et al. H₁ histamine receptor affinity predicts short term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519–26.
10.1038/sj.npp.1300027
CASPubMedWeb of Science®Google Scholar
8 Lieberman JA, Stroup TS, McEvoy JP, et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
10.1056/NEJMoa051688
CASPubMedWeb of Science®Google Scholar
9 Parsons B., Allison D., Loebel A., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103–10.
10.1016/j.schres.2008.09.025
PubMedWeb of Science®Google Scholar
10 Patel NC, Kistler JS, James EB, Crismon ML. A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 2004; 24: 824–30.
10.1592/phco.24.9.824.36091
CASPubMedWeb of Science®Google Scholar
11 Vedantam S. Silenced drug sturs an uproar. Washington Post. March 18, 2009. Available from www.washingtonpost.comwp-dyncontentarticle2009317AR2009031703786.html. Accessed April 15, 2009.
Google Scholar
12 Brecher M., Leong RW, Stening G., et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007; 68: 597–603.
10.4088/JCP.v68n0416
CASPubMedWeb of Science®Google Scholar
13 Bushe C., Sniadecki J., Bradley A., Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol 2010; 24: 1001–9.
10.1177/0269881108101783
CASPubMedWeb of Science®Google Scholar
14 McEvoy J., Lieberman J., Perkins D., et al. Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomized, double-blind 52–week comparison. Am J Psychiatry 2007; 164: 1050–60.
10.1176/ajp.2007.164.7.1050
PubMedWeb of Science®Google Scholar
15 Anderson IM, Sarsfield A., Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment-resistant depression: an open-label, pilot study. J Affect Disord 2009; 117: 116–19.
10.1016/j.jad.2008.12.016
CASPubMedWeb of Science®Google Scholar
16 Adler CM, Fleck DE, Brecher M., Strakowski SM. Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. J Affect Disord 2007; 100(suppl 1): S15–22.
10.1016/j.jad.2007.02.004
CASPubMedWeb of Science®Google Scholar
17 Hartung D., Wisdom J., Pollack D., et al. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. J Clin Psychiatry 2008; 69: 1540–7.
10.4088/JCP.v69n1003
PubMedWeb of Science®Google Scholar
18 Philip NS, Mello K., Carpenter LL, et al. Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry 2008; 20: 15–20.
10.1080/10401230701866870
PubMedWeb of Science®Google Scholar
19 Centers of Disease Control and Prevention. U.S. obesity trends. Available from www.cdc.govobesitydatatrends.html. Accessed April 15, 2009.
Google Scholar
20 Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007; 68(suppl 1): 20–7.
CASPubMedWeb of Science®Google Scholar
21 Suppes T., McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 U.S. psychiatrists. Psychopharmacol Bull 2007; 40: 22–37; quiz 38–40.
PubMedWeb of Science®Google Scholar
22 Buckley P., Miller D., Singer B., et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281–8.
10.1016/j.schres.2005.04.010
PubMedWeb of Science®Google Scholar
23 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601.
10.2337/diacare.27.2.596
PubMedWeb of Science®Google Scholar

Citing Literature

Volume30, Issue10

October 2010

Pages 1011-1015

Statistically Significant Increase in Weight Caused by Low-Dose Quetiapine

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Statistically Significant Increase in Weight Caused by Low-Dose Quetiapine

Abstract

References

Citing Literature

References

Related

Information